After Mylan uproar, a generic EpiPen could hit the market in 2017

Mylan’s EpiPen monopoly could end in 2017 as the Federal Drug Administration may speed up approval of a generic competitor.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.